Dorinem is an advanced antibiotic medication commonly used in clinical settings to address specific categories of severe bacterial infections. Its therapeutic function is considered relevant in situations involving acute, complex scenarios.

Management of Complicated Deep-Seated Infections

This medication is primarily used to help address infections categorized as complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), including severe kidney infections (pyelonephritis). It is applied in contexts marked by increased discomfort or tension related to these serious bacterial infections. These conditions often present with symptoms related to systemic imbalance, such as persistent high fever and severe, localized pain. The general therapeutic benefit involves addressing the bacterial cause of the infection, which supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Use Against Difficult-to-Treat Bacterial Strains

Dorinem is relevant in clinical scenarios where the infection may be caused by multi-drug resistant bacteria or pathogens that are proving difficult to suppress with common first-line antibiotics. It is applied across domains where additional symptomatic support is needed, commonly contributing to improved comfort during periods of heightened symptoms. The benefit involves managing the bacterial cause in complex situations, which contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Relief for Systemic Discomfort Dorinem is commonly used to help manage symptoms related to acute systemic imbalance and localized severe pain within conditions characterized by periods of heightened symptoms, such as complicated urinary tract and intra-abdominal infections.

Regulatory References

1. NIH MedlinePlus Drug Information

Dorinem (Doripenem) eligibility is strictly defined by regulatory authorities based on known hypersensitivities, age, and renal function.

Populations Excluded from Use

Contraindications (Must Not Use)

• Hypersensitivity: Patients with known serious hypersensitivity to doripenem or any other drug in the carbapenem class, or a history of anaphylactic reactions to any beta-lactam antibiotic [Source 1.5, 2.4].
• Ventilator-Associated Pneumonia (VAP): The medication is not approved for VAP due to documented lower cure rates and an increased risk of death compared to an alternative drug [Source 1.3, 2.7].
• Concurrent Medication: Use is strongly discouraged in patients taking valproic acid or sodium valproate due to the risk of reduced seizure control [Source 2.4, 2.7].

Age and Organ Function Restrictions

Population Group	Regulatory Status	Rule Basis
Pediatric Patients (< 18 years)	Not Recommended	Safety and efficacy have not been established in this age group [Source 2.1, 3.1].
Renal Impairment	Conditional Use	Patients with moderate or severe renal impairment (CrCl leq 50 mL/min) require mandatory usage adjustment; use is not recommended for patients on dialysis [Source 2.6, 3.1].
Pregnancy/Lactation	Conditional Use	Use only if clearly needed during pregnancy; caution is advised during lactation as excretion into breast milk is unknown [Source 2.1, 2.4].
Older Adults (65 years)	Allowed	No adjustment is necessary, provided the patient has normal renal function for their age [Source 2.6, 3.1].

---

Connection to the overall eligibility profile

The regulatory profile explicitly establishes absolute non-eligibility based on beta-lactam allergy and VAP, while setting conditional use parameters for patients with impaired kidney function or those taking valproic acid. These official criteria ensure the medicine is restricted to the specific adult populations where the benefit-to-risk profile has been established.

Interactions with other Medicines and Products

Dorinem (doripenem) is a carbapenem antibiotic. When starting treatment, it is important to inform your healthcare provider of all other medicines, including prescription, over-the-counter drugs, and supplements, as significant interactions can occur.

Clinically Significant Drug-Drug Interactions

Interacting Product Category	Potential Effect	Recommendation/Risk
Valproic Acid or Sodium Valproate (Anticonvulsants)	Dorinem may cause a marked reduction in the blood concentration of valproic acid.	This is not recommended due to a high risk of losing seizure control, potentially leading to breakthrough seizures, especially in patients whose seizures are already managed by this medication. Alternative anticonvulsant or antibiotic therapy should be considered.
Probenecid (Uricosuric Agent)	This medicine decreases the body's clearance of Dorinem, leading to increased Dorinem levels in the bloodstream.	This combination should generally be avoided because higher concentrations of the antibiotic can potentially increase the risk of side effects.

Other Interaction Information

• Dorinem is not expected to cause drug interactions through the major Cytochrome P450 enzyme system, as it neither inhibits nor induces these enzymes.
• As a procedural note, Dorinem must not be mixed with or physically added to solutions that contain other medications, as compatibility has not been established.

Targeted Cell Wall Synthesis Inhibition

Dorinem (doripenem) is a beta-lactam antimicrobial agent of the carbapenem class that engages mechanisms involving enzyme-mediated signaling required for the maintenance of bacterial cell integrity and replication. It primarily acts by binding to and inactivating bacterial enzymes known as Penicillin-Binding Proteins (PBPs), which are crucial for the final cross-linking step in peptidoglycan biosynthesis.

---

Modification of Structural Pathway Integrity

This engagement modifies early molecular steps that influence the systemic consequences within the pathogen by inhibiting the formation of the bacterial cell wall. The binding to key PBPs, such as PBP2 and PBP3 in specific Gram-negative organisms, modulates the pathway activity responsible for cell shape and structural integrity.

---

Consequence of Pathway Blockade

The inhibition of these vital synthesis processes ultimately leads to the destabilization of the bacterial structural barrier. This mechanism results in cell lysis, leading to the elimination of bacterial viability, which is the physiological consequence of inhibiting bacterial replication.

How Dorinem is Used: Official Administration Guidelines

Dorinem (Doripenem Monohydrate) is administered exclusively via intravenous (IV) infusion in a supervised clinical environment, utilizing the sterile powder supplied in 500 mg or 250 mg single-use vials. The powder requires a mandatory two-step protocol for proper use: initial reconstitution followed by secondary dilution in a compatible IV fluid, such as 0.9% Sodium Chloride, before it can be infused. This protocol ensures the solution is administered correctly and is not for direct injection.

The standard adult dose for approved complicated infections is 500 mg, administered every 8 hours (q8h). Each infusion is typically delivered over a period of 60 minutes. Treatment duration ranges from 5 to 14 days, depending on the specific infection type, and the protocol allows for a planned switch to an appropriate oral antibiotic to complete the course following demonstrated clinical improvement.

A crucial administration principle is the requirement for renal function-based adjustment. For patients with reduced kidney function (Creatinine Clearance, CrCl, below 50 mL/min), the standard dose is reduced to 250 mg. Furthermore, the frequency is adjusted to every 12 hours for severe impairment (CrCl 10 to less than 30 mL/min). No adjustments are required for patients with hepatic impairment, and the medication is not recommended for pediatric use as safety and efficacy have not been established.

Research evidence / Overview of studies for Dorinem

Evidence for Use in Complicated Intra-Abdominal Infections (cIAI)

Dorinem was evaluated in major research examining conditions associated with acute or disruptive episodes within the abdomen, such as complicated appendicitis, abscesses, or peritonitis. These studies were randomized trials, comparing Dorinem against active comparators. The research examined outcomes related to systemic or functional imbalance, such as the measurement of clinical response at a specified follow-up time. Findings indicate that Dorinem was observed to be associated with measurements that fell within a predefined range when compared to the antibiotic it was studied against, based on the reported measurements of clinical response and microbiological eradication at the specific follow-up visit.

Evidence for Use in Complicated Urinary Tract Infections (cUTI)

Research has explored the use of Dorinem in conditions characterized by fluctuating or episodic manifestations, including complicated bladder and kidney infections (pyelonephritis). These studies monitored outcomes related to perceived discomfort and the elimination of the specific pathogens linked to the infection. Findings indicate that Dorinem was observed to be associated with measurements that fell within a predefined range when compared to the antibiotic it was studied against, based on the reported measurements of clinical response and microbiological eradication at the specific follow-up visit.

Research in Special Patient Groups and Limitations

Studies monitored the use of Dorinem in certain patient groups, including older adults and children. For older adult patients, the research examined the outcomes in a subset of the overall study population. Findings describe patterns related to outcomes that were observed in some studies to be within the expected range when compared to younger adults. Dedicated research explored the use of Dorinem in children with complicated infections. However, sample sizes were modest for these specific subgroups, meaning that subgroup findings are uncertain. Data for certain groups, such as very young infants, remain insufficient, and the results apply only to the pediatric populations studied in those trials.

The clinical trials primarily involved studies observing responses over defined time intervals, typically spanning a few weeks after the treatment concluded. Long-term effects are not fully established; there is limited information for long-term outcomes, meaning the research does not determine whether an individual will experience a recurrence far into the future.

Key Studies & References

1. Doripenem Trial Halted Due to Higher Mortality Rate (Ventilator-Associated Pneumonia - VAP Trial Context)
2. The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled Trials (covering cIAI, cUTI, VAP)

Common questions about Dorinem (FAQ)

Q: If I miss a dose of Dorinem, what should I do?

A: General patient counseling information for this class of medicine suggests that the regulatory standard is to use the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the standard is to skip the missed one to maintain the regular dosing schedule. Official guidance advises against taking a double dose to compensate for a missed dose.

---

Q: Can Dorinem affect my blood pressure?

A: Official safety data indicates that Dorinem may be associated with changes in blood pressure. An increase in blood pressure has been listed as a less common side effect in the official product information.

---

Q: What is the maximum number of days I can be on Dorinem?

A: The official product information specifies the approved duration of treatment based on the infection type. For complicated intra-abdominal infections, the treatment course is generally up to 14 days. For complicated urinary tract infections, the course is typically up to 10 days, or 14 days if a concurrent blood infection (bacteremia) is present.

---

Q: Is there any food or drink I need to avoid while on Dorinem?

A: According to the official prescribing information, there are no specific food or drink interactions listed for Dorinem. The medication is delivered intravenously, and the label does not recommend any dietary restrictions while receiving treatment.

---

Q: What should I do if the Dorinem IV bag looks cloudy or has particles?

A: Regulatory preparation guidelines specify that the reconstituted IV solution should be visually inspected prior to use. The solution is expected to be clear, ranging from colorless to slightly yellow. If particulate matter (undissolved bits) or cloudiness is observed, the product should not be administered.

---

Q: What happens if Dorinem is injected directly into the vein instead of being infused?

A: The official product label mandates that Dorinem must be diluted and administered as a slow intravenous (IV) infusion over a set period of time. The product information states the medication is not approved for direct, rapid injection into a vein. The regulatory documents do not specify the consequences of administering the medication incorrectly.

How to Store and Dispose of Dorinem

Dorinem (doripenem for injection) is supplied as a sterile powder in a single-use vial. All storage and disposal procedures must strictly follow government-approved labeling.

---

Storage Requirements

Unopened Vial: The sterile powder must be stored in its original package to protect it from light. It must be maintained at a controlled room temperature, typically below 30 C.

Prepared Solutions: The reconstituted or diluted solution must not be frozen. Stability limits depend on the solvent and temperature, as defined in the following table.

Infusion Solution	Maximum Stability at Room Temperature (25 C)	Maximum Stability Under Refrigeration (2 C to 8 C)
0.9% Sodium Chloride	12 hours	72 hours
5% Dextrose	4 hours	24 hours

The product must also be kept out of the sight and reach of children.

---

Disposal

The vial is for single use. Any unused product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste.